Aduro Biotech (ADRO) has been under a strong bear grip, hence the stock is down -0.91% when compared to the S&P 500 in the past 4 weeks. However, in the near-term, buying emerged at lower levels and the stock has outperformed the S&P 500 by 4.75% in the past 1 week. The stock has risen by 5.31% in the past week indicating that the buyers are active at lower levels, but the stock is down -2.91% in the past 4 weeks.
The stock has recorded a 20-day Moving Average of 1.95% and the 50-Day Moving Average is 2.4%.The 200 Day SMA reached 7.46% Aduro BioTech, Inc. is up 30.17% in the last 3-month period. Year-to-Date the stock performance stands at -47.87%.
Aduro Biotech (ADRO) : The highest level Aduro Biotech (ADRO) is projected to reach is $22 for the short term and the lowest estimate is at $11. The consolidated price target from 4 rating analysts who initiate coverage on the stock is $17.25 and the possibility the share price can swing is $5.62.
For the current week, the company shares have a recommendation consensus of Buy. Aduro Biotech (NASDAQ:ADRO): The stock opened at $13.98 and touched an intraday high of $14.86 on Friday. During the day, the stock corrected to an intraday low of $13.9, however, the bulls stepped in and pushed the price higher to close in the green at $14.67 with a gain of 4.56% for the day. The total traded volume for the day was 1,034,636. The stock had closed at $14.67 in the previous trading session.
Aduro BioTech Inc is a United States-based clinical-stage immunotherapy company. The Company has developed or acquired technology platforms designed to activate potent and lasting immune responses against cancer: live, attenuated Listeria, GVAX and cyclic dinucleotides (CDNs). Aduros lead program is an immunotherapy regimen combining Listeria-based CRS-207 and GVAX Pancreas in patients with metastatic pancreatic cancer who have failed at least one therapy. Its pipeline includes CRS-207, ADU-623, ADU-214, ADU-741, CDN and STINGVAX. CRS-207 is based on Aduros Listeria platform. ADU-623 is Aduros first clinical bivalent Listeria-based immunotherapy. ADU-214 is a bivalent Listeria-based immunotherapy that targets both mesothelin and an EGFR mutation. CDNs are small molecules that signal through STING and induce a potent immune response. STINGVAX is the combination of CDNs and GVAX.